Bone morphogenetic proteins

PLN-1474 (compound 1) is an orally active and selective av?1 integrin inhibitor with an IC 50 value of In VitroPLN-1474 inhibits ανβ1 and ανβ6 with IC 50 s of In VivoPLN-1474 (10 μM) decreases the expression level of profibrotic genes, including

PLN-1474 (compound 1) is an orally active and selective av?1 integrin inhibitor with an IC 50 value of In VitroPLN-1474 inhibits ανβ1 and ανβ6 with IC 50 s of In VivoPLN-1474 (10 μM) decreases the expression level of profibrotic genes, including

PLN-1474 (compound 1) is an orally active and selective av?1 integrin inhibitor with an IC 50 value of In VitroPLN-1474 inhibits ανβ1 and ανβ6 with IC 50 s of In VivoPLN-1474 (10 μM) decreases the expression level of profibrotic genes, including

RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activityIn VitroRO0270608 inhibits α4/β7 mediated cell adhesion with an IC50 of 33 nM. In a human T-cell VCAM/anti CD3

RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activityIn VitroRO0270608 inhibits α4/β7 mediated cell adhesion with an IC50 of 33 nM. In a human T-cell VCAM/anti CD3

RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activityIn VitroRO0270608 inhibits α4/β7 mediated cell adhesion with an IC50 of 33 nM. In a human T-cell VCAM/anti CD3

RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activityIn VitroRO0270608 inhibits α4/β7 mediated cell adhesion with an IC50 of 33 nM. In a human T-cell VCAM/anti CD3

RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activityIn VitroRO0270608 inhibits α4/β7 mediated cell adhesion with an IC50 of 33 nM. In a human T-cell VCAM/anti CD3

RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activityIn VitroRO0270608 inhibits α4/β7 mediated cell adhesion with an IC50 of 33 nM. In a human T-cell VCAM/anti CD3

Sevasemten is an allosteric inhibitor of skeletal muscle myosin. Sevasemten exhibits selectively myosin inhibition with IC 50 s of ≤10 μM (skeletal), &gt100 μM (cardiac), respectively.Form:Solid

Sevasemten is an allosteric inhibitor of skeletal muscle myosin. Sevasemten exhibits selectively myosin inhibition with IC 50 s of ≤10 μM (skeletal), &gt100 μM (cardiac), respectively.Form:Solid

Sevasemten is an allosteric inhibitor of skeletal muscle myosin. Sevasemten exhibits selectively myosin inhibition with IC 50 s of ≤10 μM (skeletal), &gt100 μM (cardiac), respectively.Form:Solid